/EVOK
EVOK Stock - Evoke Pharma, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$11.00+0.00%
+$11.00 (+0.00%) • Dec 16
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+63.6%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EVOK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.89 – $11.11
TARGET (TP)$18.00
STOP LOSS$10.12
RISK/REWARD1:8.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.14
52W High$11.00
52W Low$1.94
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.25M | $5.18M | $2.51M | $1.62M | $23,020 |
| Gross Profit | $9.89M | $4.98M | $2.14M | $1.29M | $-63,692 |
| Gross Margin | 96.5% | 96.1% | 85.2% | 79.7% | -276.7% |
| Operating Income | $-5,204,137 | $-7,430,891 | $-7,786,137 | $-8,151,647 | $-13,047,349 |
| Net Income | $-5,352,194 | $-7,792,295 | $-8,224,130 | $-8,537,952 | $-13,154,671 |
| Net Margin | -52.2% | -150.4% | -327.8% | -527.7% | -57144.5% |
| EPS | $-2.81 | $-27.97 | $-31.16 | $-40.40 | $-74.91 |
Company Overview
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EVOKBeat Rate
0%
Last 18 quarters
Avg Surprise
-2384.1%
EPS vs Estimate
Beats / Misses
0/17
1 met exactly
Latest EPS
$-0.45
Q4 2025
EPS Surprise History
Q1 24
-1316.0%
$-7.08vs$-0.50
Q2 24
-871.4%
$-2.04vs$-0.21
Q3 24
-29.2%
$-0.93vs$-0.72
Q4 24
-147.4%
$-0.94vs$-0.38
Q1 25
-96.0%
$-0.49vs$-0.25
Q2 25
-54.5%
$-0.51vs$-0.33
Q3 25
-37.8%
$-0.62vs$-0.45
Q4 25
0.0%
$-0.45vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.45 | $-0.45 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.45 | $-0.62 | -37.8% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.33 | $-0.51 | -54.5% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.25 | $-0.49 | -96.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.38 | $-0.94 | -147.4% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.72 | $-0.93 | -29.2% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.21 | $-2.04 | -871.4% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.50 | $-7.08 | -1316.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.62 | $-6.12 | -887.1% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.73 | $-6.72 | -820.5% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.58 | $-8.04 | -1286.2% | ✗ MISS |
Q1 2023 | Mar 21, 2023 | $0.53 | $-6.36 | -1300.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.66 | $-7.20 | -990.9% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.60 | $-8.52 | -1320.0% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-5.77 | $-10.09 | -75.0% | ✗ MISS |
Q1 2022 | Mar 8, 2022 | $-0.08 | $-7.21 | -8912.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.07 | $-8.65 | -12257.1% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.08 | $-10.09 | -12512.5% | ✗ MISS |
Latest News
Biogen shares are trading higher after Novo Nordisk's Evoke Phase 3 trials did not show a statistically significant reduction in Alzheimer's disease progression.
📈 PositiveBenzinga•Nov 24, 2025, 12:48 PM•Also: ,
Novo Nordisk shares are trading lower after Evoke Phase 3 trials data showed that GLP-1 drugs did not demonstrate statistically significant reduction in Alzheimer's disease progression.
📉 NegativeBenzinga•Nov 24, 2025, 11:46 AM•Also:
Novo Nordisk Announced Evoke Phase 3 Trials Did Not Demonstrate Statistically Significant Reduction In Alzheimer's Disease Progression
📉 NegativeBenzinga•Nov 24, 2025, 11:26 AM•Also:
Evoke Pharma Q3 EPS $(0.45), Inline, Sales $4.284M Miss $4.326M Estimate
➖ NeutralBenzinga•Nov 13, 2025, 12:14 PM
Evoke Pharma shares are trading higher after the company announced it entered into a definitive agreement to be acquired by QOL Medical.
📈 PositiveBenzinga•Nov 4, 2025, 02:20 PM
Evoke Pharma soars on announcement to be acquired by QOL Medical
📈 PositiveSeeking Alpha•Nov 4, 2025, 01:00 PM
Evoke Pharma Enters Definitive Agreement To Be Acquired By QOL Medical For $11/Share In Cash
📈 PositiveBenzinga•Nov 4, 2025, 12:13 PM
Evoke Pharma And EVERSANA Expand GIMOTI® Access Through Omnicell Partnership With Gastro Health And Large GI Practices, Add OneGI Via Brentwood Pharmacy, Nearly Doubling Specialty Pharmacy Network
📈 PositiveBenzinga•Aug 26, 2025, 11:12 AM•Also:
Shares are trading higher after the company announced the listing of a new GIMOTI patent in the FDA Orange Book.
📈 PositiveBenzinga•Aug 21, 2025, 03:24 PM
Market-Moving News for August 21st
➖ NeutralBenzinga•Aug 21, 2025, 11:22 AM•Also: ,
Evoke Pharma Highlights Newly Listed US Patent For GIMOTI In FDA Orange Book With Expiration Date of November 17, 2038
📈 PositiveBenzinga•Aug 21, 2025, 11:07 AM
Evoke Pharma Posts 47 Percent Q2 Growth
📈 PositiveThe Motley Fool•Aug 14, 2025, 11:16 AM
Frequently Asked Questions about EVOK
What is EVOK's current stock price?
Evoke Pharma, Inc. (EVOK) is currently trading at $11.00 per share. The stock has moved +0.00% today.
What is the analyst price target for EVOK?
The average analyst price target for EVOK is $18.00, based on 1 analyst.
What sector is Evoke Pharma, Inc. in?
Evoke Pharma, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is EVOK's market cap?
Evoke Pharma, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does EVOK pay dividends?
No, Evoke Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
BFRI
Biofrontera Inc.
$0.77
Mkt Cap: $0.0B
BMRA
Biomerica, Inc.
$2.31
Mkt Cap: $0.0B
MHUA
Meihua International Medical Technologies Co., Ltd.
$7.09
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
SBFM
Sunshine Biopharma, Inc.
$1.39
Mkt Cap: $0.0B
SNOA
Sonoma Pharmaceuticals, Inc.
$3.57
Mkt Cap: $0.0B
SSKN
STRATA Skin Sciences, Inc.
$1.19
Mkt Cap: $0.0B
YCBD
cbdMD, Inc.
$1.51
Mkt Cap: $0.0B
Explore stocks similar to EVOK for comparison